Haleon plc (LON:HLN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Haleon plc (LON:HLN) have been assigned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is GBX 407.83.

Several brokerages have recently issued reports on HLN. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 450 price target on shares of Haleon in a report on Wednesday. Berenberg Bank upped their price objective on Haleon from GBX 507 to GBX 517 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 370 target price on shares of Haleon in a report on Friday, October 31st. JPMorgan Chase & Co. boosted their target price on Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a research report on Wednesday, November 26th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Haleon from GBX 340 to GBX 335 and set a “buy” rating for the company in a research report on Thursday.

Haleon Price Performance

Haleon stock traded up GBX 2.48 during mid-day trading on Thursday, reaching GBX 379.68. 132,636,219 shares of the company’s stock traded hands, compared to its average volume of 85,014,141. Haleon has a 12-month low of GBX 325.10 and a 12-month high of GBX 419.50. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The stock has a 50 day moving average of GBX 368.53 and a two-hundred day moving average of GBX 359.19. The company has a market cap of £33.81 billion, a price-to-earnings ratio of 22.74, a PEG ratio of 1.49 and a beta of 0.19.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.